Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2005

Open Access 01-12-2005 | Research

Evidence that 17alpha-estradiol is biologically active in the uterine tissue: Antiuterotonic and antiuterotrophic action

Authors: Mercedes Perusquía, Erika Navarrete

Published in: Reproductive Biology and Endocrinology | Issue 1/2005

Login to get access

Abstract

Background

17alpha-Estradiol has been considered as the hormonally inactive isomer of 17beta-estradiol. Recently, nongenomic (smooth muscle relaxation) and genomic (light estrogenic activity) effects of 17alpha-estradiol have been reported, but no reports have yet determined its possible antiestrogenic activity. Therefore, this study investigated: the nongenomic action of 17alpha-estradiol on uterine contractile activity and its potential agonist-antagonist activity on uterine growth.

Methods

Uterine rings from rats were isometrically recorded. Different concentrations (0.2–200 microM) of 17alpha-estradiol were tested on spontaneous contraction and equimolarly compared with 17beta-estradiol. To examine the mechanism of 17alpha-estradiol action, its effect was studied in presence of beta2-antagonist (propranolol), antiestrogens (tamoxifen and ICI 182,780) or inhibitors of protein synthesis (cycloheximide) and transcription (actinomycin D). Moreover, contractions induced by high potassium (KCl) solution or calcium in depolarized tissues by KCl-calcium free solution were exposed to 17alpha-estradiol. Collaterally, we performed an uterotrophic assay in adult ovariectomized rats measuring the uterine wet weight. The administration for three days of 0.3 microM/day/Kg 17beta-estradiol was equimolarly compared with the response produced by 17alpha-estradiol. Antiuterotrophic activity was assayed by administration of 0.3 microM/day/Kg 17beta-estradiol and various doses ratios (1:1, 1:3, 1:5, and 1:100) of 17alpha-estradiol.

Results

The estradiol isomers elicited an immediate relaxation, concentration-dependent and reversible on spontaneous contraction. 17alpha-Estradiol presented lower potency than 17beta-estradiol although it did not antagonize 17beta-estradiol-induced relaxation. Relaxation to 17alpha-estradiol was not inhibited by propranolol, tamoxifen, ICI 182,780, cycloheximide or actinomycin D. The KCl contractions were also sensitive to 17alpha-estradiol-induced relaxation and calcium contractions in depolarized tissues were markedly prevented by 17alpha-estradiol, implying a reduction of extracellular calcium influx through voltage-operated calcium channels (VOCCs). Uterotrophic assay detected significant increase in uterine weight using 17alpha-estradiol, which was significantly minor as compared with 17beta-estradiol. 17alpha-Estradiol, at all doses ratios, significantly antagonized the hypertrophic response of 17beta-estradiol.

Conclusion

17alpha-Estradiol induces a relaxing effect, which may be independent of the classical estrogen receptor, nongenomic action, apparently mediated by inactivation of VOCCs. 17alpha-Estradiol is also a weak estrogen agonist (uterotrophic response); likewise, 17alpha-estradiol may act as an antiestrogen (antiuterotrophic response). The overall data document a nongenomic relaxing action and a novel antiestrogenic action of 17alpha-estradiol, which are relevant in estrogen-mediated uterine physiology.
Appendix
Available only for authorised users
Literature
1.
Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC: 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992, 89: 883-891.PubMedCentralCrossRefPubMed
2.
Vargas R, Tomas G, Wroblewska B, Ramwell PW: Differential effects of 17α and 17β-estradiol on PGF2α mediated contraction of the porcine coronary artery. Adv Prostaglandin Thromboxane Leukot Res. 1989, 19: 277-280.PubMed
3.
Pietras RJ, Szego CM: Estrogen receptors in uterine plasma membrane. J Steroid Biochem. 1979, 11: 1471-1483. 10.1016/0022-4731(79)90124-9.CrossRefPubMed
4.
Merriam GR, MacLusky NJ, Johnson LA, Naftolin F: 2-Hydroxyestradiol-17α and 4-hydroxyestradiol-17α, catechol estrogen analogs with reduced estrogen receptor affinity. Steroids. 1980, 36: 13-20. 10.1016/0039-128X(80)90063-X.CrossRefPubMed
5.
Schwartz Z, Soskolne WA, Neubauer T, Goldstein M, Adi S, Ornoy A: Direct and sex-specific enhancement of bone formation and calcification by sex-steroids in fetal mice long bone in vitro (biochemical and morphometric study). Endocrinology. 1991, 129: 1167-1174.CrossRefPubMed
6.
Nasatzky E, Schwartz Z, Boyan BD, Soskolne WA, Ornoy A: Sex dependent effects of 17-beta-estradiol on chondrocyte differentiation in culture. J Cell Physiol. 1993, 154: 359-367. 10.1002/jcp.1041540220.CrossRefPubMed
7.
Lundeen SG, Carver JM, McKean ML, Winneker RC: Characterization of ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology. 1997, 138: 1552-1558. 10.1210/en.138.4.1552.CrossRefPubMed
8.
Hajek RA, Robertson AD, Johnston DA, Van NT, Tcholakian RK, Wagner LA, Conti CJ, Meistrich ML, Contreras N, Edwards CL, Jones LA: During development, 17alpha-estradiol is a potent estrogen and carcinogen. Environ Health Perspect. 1997, 3: 577-581.
9.
Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Imatanaka N, Takatsuki M: Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-three chemicals. Toxicology. 2002, 170: 21-30. 10.1016/S0300-483X(01)00505-4.CrossRefPubMed
10.
Yamasaki K, Takeyoshi M, Sawaki M, Imatanaka N, Shinoda K, Takatsuki M: Immature rat uterotrophic assay of 18 chemicals and Hershberger assay of 30 chemicals. Toxicology. 2003, 183: 93-115. 10.1016/S0300-483X(02)00445-6.CrossRefPubMed
11.
Fujimoto N, Honda H, Kitamura S: Effects of environmental estrogenic chemicals on AP1 mediated transcription with estrogen receptors α and β. J Steroid Biochem Mol Biol. 2004, 88: 53-59. 10.1016/j.jsbmb.2003.10.006.CrossRefPubMed
12.
Green PS, Bishop J, Simpkins JW: 17α-estradiol exerts neuroprotective effects on SK-N-SH cells. J Neorosci. 1997, 17: 511-515.
13.
Dicko A, Morissette M, Ben Ameur S, Pezolet M, Di Paolo T: Effect of estradiol and tamoxifen on brain membranes: investigation by infrared and fluorescence spectroscopy. Brain Res Bull. 1999, 49: 401-405. 10.1016/S0361-9230(99)00066-0.CrossRefPubMed
14.
Morin C, Zini R, Simon N, Tillement JP: Dehydroepiandrosterone and α-estradiol limit the functional alterations of rat brain mitochondria submitted to different experimental stress. Neuroscience. 2002, 115: 415-424. 10.1016/S0306-4522(02)00416-5.CrossRefPubMed
15.
Salas E, López MG, Villarroya M, Sánchez-García P, De Pascua R, Dixon WR, García AG: Endothelium-independent relaxation by 17-α-estradiol of pig coronary arteries. Eur J Pharmacol. 1994, 258: 47-55. 10.1016/0014-2999(94)90056-6.CrossRefPubMed
16.
Rodríguez J, García de Boto MJ, Hidalgo A: Mechanisms involved in the relaxant effect of estrogens on rat aorta strips. Life Sci. 1996, 58: 607-615. 10.1016/0024-3205(95)02330-5.CrossRefPubMed
17.
Seeger H, Mueck AO, Ottel M, Schwarz S, Lippert TH: Calcium antagonistic effect of 17 alpha-estradiol derivatives: in vitro examinations. Gynecol Endocrinol. 1999, 13: 246-248.CrossRefPubMed
18.
Gutiérrez M, Fernández AI, Revuelta MP, Cantabrana B, Hidalgo A: Partial contribution to the relaxant effect of 17α-estradiol in rat uterine smooth muscle. Gen Pharmacol. 1998, 30: 71-77.CrossRefPubMed
19.
Ratz PH, McCammon KA, Altstatt D, Blackmore PF, Shenfeld OZ, Schlossberg SM: Differential effects of sex hormones and phytoestrogens on peack and steady state contractions in isolated rabbit detrusor. J Urol. 1999, 162: 1821-1828. 10.1097/00005392-199911000-00077.CrossRefPubMed
20.
Sievernich A, Wildt L, Lichtenberg-Frate H: In vitro bioactivity of 17α-estradiol. J Steroid Biochem Mol Biol. 2004, 92: 455-463. 10.1016/j.jsbmb.2004.09.004.CrossRefPubMed
21.
Hobe G, Schon R, Goncharov N, Katsiya G, Koryakin M, Gesson-Cholat I, Oettel M, Zimmermann H: Some new aspects of 17α-estradiol metabolism in man. Steroids. 2002, 67: 883-893. 10.1016/S0039-128X(02)00058-2.CrossRefPubMed
22.
Bhavnani BR: Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol. 2003, 85: 473-482. 10.1016/S0960-0760(03)00220-6.CrossRefPubMed
23.
Perusquía M, Hernández R, Kubli-Garfias C: Epitestosterone induces testosterone-like uterine relaxation [abstract]. 10th International Congress of Endocrinology. 1996, 549: 578-
24.
Nuck BA, Lucky AW: Epitestosterone: a potential new antiandrogen. J Invest Dermatol. 1987, 89: 209-211. 10.1111/1523-1747.ep12470564.CrossRefPubMed
25.
Starká I, Bicíková M, Hampl R: Epitestosterone -an endogenous antiandrogen?. J Steroid Biochem. 1989, 33: 1019-1021. 10.1016/0022-4731(89)90255-0.CrossRefPubMed
26.
Bicíková M, Hampl R, Starká L: Epitestosterone a potent competitive inhibitor of C21-steroid side chain cleavage in testis. J Steroid Biochem Mol Biol. 1992, 43: 721-724. 10.1016/0960-0760(92)90298-W.CrossRefPubMed
27.
Lictchfield JT, Wilcoxon FA: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949, 96: 99-108.
28.
Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000, 103: 843-852. 10.1016/S0092-8674(00)00188-4.CrossRefPubMed
29.
Perusquía M: Nongenomic action of steroids in myometrial contractility. Endocrine. 2001, 15: 63-72. 10.1385/ENDO:15:1:063.CrossRefPubMed
30.
Perusquía M, Jasso-Kamel J: Influence of 5α- and 5β-reduced progestins on the contractility of isolated human myometrium at term. Life Sci. 2001, 68: 2933-2944. 10.1016/S0024-3205(01)01089-X.CrossRefPubMed
31.
Perusquía M, Navarrete E, Jasso-Kamel J, Montaño LM: Androgens induce relaxation of contractile activity in pregnant human myometrium at term: a nongenomic action on L-type calcium channels. Biol Reprod. 2005, 10.1095/biolreprod.104.036954
32.
Perusquía M, García-Yañez E, Ibáñez R, Kubli-Garfias C: Non-genomic mechanism of action of Δ4 and 5-reduced androgens and progestins on the contractility of isolated rat myometrium. Life Sci. 1990, 47: 1547-1553. 10.1016/0024-3205(90)90183-R.CrossRefPubMed
33.
Perusquía M, Villalón CM: Posible role of Ca2+ channels in the vasodilating effect of 5β-dihydrotestosterone in rat aorta. Eur J Pharmacol. 1999, 371: 169-178. 10.1016/S0014-2999(99)00161-2.CrossRefPubMed
34.
Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA: Cardiovascular protection by oestrogen -a calcium antagonist effect?. Lancet. 1993, 341: 1264-1265. 10.1016/0140-6736(93)91158-I.CrossRefPubMed
35.
Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT: Effect of 17β-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 1992, 106: 739-745.PubMedCentralCrossRefPubMed
36.
Zhang F, Ram JL, Standley PR, Sower JR: 17β-estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol. 1994, 266: C975-C980.PubMed
37.
Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 1995, 9: 404-410.PubMed
38.
Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999, 13: 307-319. 10.1210/me.13.2.307.PubMed
39.
Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW: ERβ has nongenomic action in caveolae. Mol Endocrinol. 2002, 16: 938-946. 10.1210/me.16.5.938.PubMed
40.
Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER: Plasma membrane estrogen receptors exist and function as dimmers. Mol Endocrinol. 2004, 18: 2854-2865. 10.1210/me.2004-0115.CrossRefPubMed
41.
Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W, Hass BS, Xie Q, Dial SL, Moland CL, Sheehan DM: Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol. 2001, 14: 280-294. 10.1021/tx000208y.CrossRefPubMed
42.
Agarwal AK, Bindal RD: Estrogen receptor-binding affinity of tamoxifen analogs with various side chains and their biologic profile in immature rat uterus. Steroids. 1991, 56: 486-489. 10.1016/0039-128X(91)90007-I.CrossRefPubMed
43.
Lipton A, Vinijsanum A, Martin L: Acute inhibition of rat myometrial responses to oxytocin by tamoxifen stereoisomers and oestradiol. J Endocrinol. 1984, 103: 383-388.CrossRefPubMed
44.
Fernández AI, Cantabrana B, Hidalgo A: Estrogen and antiestrogen non-genomic effect in rat uterus contraction in calcium-free solution. Gen Pharmacol. 1993, 24: 391-395.CrossRefPubMed
45.
Kostrzewska A, Laudanski T, Batra S: Potent inhibition by tamoxifen of spontaneous and agonist-induced contractions of the human myometrium and intramyometrial arteries. Am J Obstet Gynecol. 1997, 176: 381-386.CrossRefPubMed
46.
Altan N, Chen Y, Schindler M, Simon SM: Tamoxifen inhibits acidification in cells independent of estrogen receptor. Proc Natl Acad Sci. 1999, 96: 4432-4437. 10.1073/pnas.96.8.4432.PubMedCentralCrossRefPubMed
47.
Korach KS: Insights from the study of animals lacking functional estrogen receptor. Science. 1994, 266: 1524-1527.CrossRefPubMed
48.
Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997, 11: 657-666. 10.1210/me.11.6.657.CrossRefPubMed
49.
McDonnell DP: The molecular pharmacology of SERMs. Trends Endocrinol Metab. 1999, 10: 301-311. 10.1016/S1043-2760(99)00177-0.CrossRefPubMed
50.
Levin ER: Integration of the extra-nuclear and nuclear actions of estrogen. Mol Endocrinol. 2005, 10.12107me.2004-0390
51.
Zhang H, McElrath T, Tong W, Pollard JW: The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation. J Endocrinol. 2005, 184: 129-140. 10.1677/joe.1.05987.CrossRefPubMed
Metadata
Title
Evidence that 17alpha-estradiol is biologically active in the uterine tissue: Antiuterotonic and antiuterotrophic action
Authors
Mercedes Perusquía
Erika Navarrete
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2005
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/1477-7827-3-30

Other articles of this Issue 1/2005

Reproductive Biology and Endocrinology 1/2005 Go to the issue

Research

Increase of mitochondrial DNA content and transcripts in early bovine embryogenesis associated with upregulation of mtTFA and NRF1 transcription factors

Research

Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro

Review

Reactive oxygen species in spermatozoa: methods for monitoring and significance for the origins of genetic disease and infertility

Research

Interferon-gamma alters the phagocytic activity of the mouse trophoblast

Research

Molecular cloning and characterization of a nuclear androgen receptor activated by 11-ketotestosterone

Research

Effects of ICI 182780 on estrogen receptor expression, fluid absorption and sperm motility in the epididymis of the bonnet monkey